Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that new oral agents from Endo Pharmaceuticals and Cephalon will drive sales in the acute pain drug market to reach more than $22 billion in 2015.
The new Pharmacor report Opportunities in Acute Pain finds that Endo Pharmaceuticals' immediate-release and extended-release formulations of oxymorphone -- Opana and Opana ER -- as well as Johnson & Johnson's IONSYS (fentanyl iontophoresis system) and Cephalon's Fentora (effervescent buccal fentanyl tablet) will help drive steady annual growth in the acute pain market during the 2005-2015 study period. While the pipeline holds no clear blockbusters, the unmet need in segments such as breakthrough cancer pain and postoperative pain has the potential to propel IONSYS and Fentora past $200 million each in sales.
Additionally, the launches during the next ten years of new formulations of opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and local anesthetics will further fragment the acute pain market. The report also finds that the acute pain market in the United States, Japan, France, Germany, Italy, Spain, and the United Kingdom continues to rebound from the loss of selective cyclooxygenase-2 (COX-2) inhibitors, including the highly publicized withdrawal in 2004 of Merck's Vioxx over safety concerns.
"The COX-2 inhibitor class was quite popular with primary care physicians and pain specialists alike because many believed the dangers associated with this class were not a significant issue in short-term use," said Michelle Grady, therapeutic area director at Decision Resources, Inc. "Physicians have expressed dismay at the sudden void in treatment options and, for the most part, they have filled the gap by reverting to traditional NSAIDs, weak opioids such as Johnson & Johnson's Ultram (tramadol), and generics."
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/